Reports

The Snippet : HER2 Expression and its Dynamic Functional States within Circulating Breast Cancer Cells

Posted on Updated on

A research published in Nature recently identified some dynamic functional states in the breast cancer cells of HER2 breast cancer. The research postulates that women who have advanced oestrogen-receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, are prone to acquire a HER2-positive subpopulation after multiple courses of therapy. This acquired heterogeneity during the cancer evolution was previously unknown, and to find out the same the researchers evaluated women with ER+/HER2 primary tumours. The results show that the HER2 circulating tumour cells have shown activation of Notch and DNA damage pathways, which results in resistance to cytotoxic chemotherapy. HER2+ and HER2 circulating tumour cells are able to convert among themselves and produce daughter cells that are opposite within four cell doublings. Even though both HER2+ and HER2 tumour cells found in circulation were comparable in tumour initiating potential, differential proliferation favours the HER2+ state, while oxidative stress or cytotoxic chemotherapy enhances transition to the HER2 phenotype. Thus, these results point to some very distinct yet interconverting phenotypes present within patient population and also contributes in the progression of breast cancer and acquisition of drug resistance.

To know more, click on the link below:

http://www.nature.com/nature/journal/v537/n7618/full/nature19328.html

Advertisements

Futuristic Customizable RNA Vaccine

Posted on Updated on

A vaccine is a biological cocktail composed of inactive microorganisms that are either attenuated or dead. It has been found that human immune system maintains a memory of disease causing agents to save the body from the next attack. But vaccines till date are known to treat only specific type of ailments.

To overcome this limitation, scientists at Massachusetts Institute of Technology (MIT) are working towards the development of customized vaccines that could work against  a vast array of agents viz. Ebola, Zika and other disease outbreaks, and could be deployed faster than traditional vaccines. This nanoformulation lead to development of vaccine that can be prepared in a week’s time and helps in faster deployment. Till date researchers have tried and tested this vaccine in animal models such as mice and it has shown effective response towards against Ebola, H1N1 influenza and Toxoplasma gondii.

These vaccines consist of RNA strands that can be designed to code any viral, bacterial or parasitic proteins. This RNA is then delivered into cells where it is translated into proteins that instills effective immune response from pathogenic host.  Besides infectious diseases, vaccines that can act on cancerous cells are also a research focus. RNA has always fascinated scientists as it can induce production of multiple copies of immune cells and by customizing the RNA sequences, the researchers can design vaccines that can produce nearly any protein of choice.

In the study conducted by Dr. Jasdave Chahal and Dr. Omar Khan, Dr Khan designed the RNA particles in which they packed the RNA vaccine in dendrimers that can be positively charged hence can form successful close association with negatively charged RNA molecules of about 150 nanometers. This size is similar to that of many viruses, hence enabling them to enter the cells by surface proteins that viruses use. When the particle enters into the system, the RNA swiftly translates into proteins that are released and stimulate the immune system. This further stimulated both T cell response and an antibody response of immune system.

These customized RNA vaccines can prove to be highly beneficial in treating influenza. As the most common flu vaccine manufacturing method involves growing the virus inside the chicken eggs, that takes months. This new approach of vaccine development is indeed a revolutionary one in the medical domain as it could reduce the manufacturing time dramatically after the disease outbreak. This vaccine can be safer alternative to DNA vaccines because unlike DNA, RNA doesn’t integrate in host genome and cause mutations.

Researchers are quite hopeful about this discovery and looking forward for further successful development in this vertical. If it goes well it can revolutionize the medical world with a new dawn of faster mode of immunization.

Insight by Anurag Mathur
Associate Analyst
DelveInsight Business Research

 

Nav1.7 Blockers- New Genre of Pain Relief Therapy

Posted on Updated on

Voltage-gated sodium channels are membrane proteins, a polypeptide chain of more than 1800 amino acids that conduct sodium ions at high rates. They are embedded in the plasma membrane and are actively present in the nerve and muscle cells used in the rapid electrical signaling. Nav channels are therapeutic targets for many cardiovascular and neurological disorders. The different subtypes of voltage gated sodium channel include Nav1.1, Nav1.2, Nav1.3, Nav1.4, Nav1.5, Nav1.6, Nav1.7, Nav1.8 and Nav1.9 channels.

Nav1.7 is involved in early phases of neuronal electrogenesis. Mutations in Nav1.7 channel can caused Familial Rectal Pain (FRP) and Paroxysmal Extreme Pain Disorder (PEPD) in humans. Studies by James Cox and Geoff Woods et al. have demonstrated that Nav1.7 leads to pain signaling and generation in humans. Mutation in T2573A and T2543C in Nav1.7 can cause primary erythermalgia. Nav1.7 acts as a promising target in the pain perception pathway. Blockers of Nav1.7 channels have great potential as analgesics, and therapy for the treatment of chronic pain including dental pain, pain associated with osteoarthritis, erythromelalgia, diabetic neuropathy, peroxymal extreme pain disorder (PEPD), neuropathic pain and ocular pain. Benzazepinone, amino-thiazoles, amino-pyridines and isoxazoles are inhibitors of Nav1.7 that provide the desired treatment for pain with fewer side effects. ProTx-II isolated from tarantula Thrixopelma prurient is blocker of Nav1.7 channels. Peptides that are present in venoms of snakes and spiders are also the source ion channel blockers.

Currently, there are some major companies that involved in Nav 1.7 blocker drugs development including Amgen, Biogen, Genentech, Teva Pharmaceuticals, and Sumitomo Dainippon. These companies are in initial phase of development with drugs either in Preclinical stage of development or in Phase I stage.

These Nav 1.7 blockers are on the hit list of companies and it’s quite evident with active alliances and acquisitions that they are working with great hopes towards it. The joint venture of Purdue Pharma and AnaBios Corporation in the year 2015 is a sign that researchers have found this compound to be of great commercial value and hence companies are moving ahead in the domain of chronic pain treatment using AnaBios’ Phase-X technology. Not only this, in January 2016 Biogen acquired Convergence Pharmaceuticals that brings along Convergence’s Phase 2 chronic pain compound CNV1014802 to Biogen, thereby expanding their chronic pain portfolio.

Nav1.7 blockers have an edge over other conventional blockers as they are more targets specific and can also be used to deliver non-selective local anesthetic. Nav1.7 blockers prevent motor side effects that occur due to other pain relief therapies. Preclinical studies that are ongoing have shown satisfactory results till now with very few cases of adverse effects and in future we can assume that Nav1.7 blockers can come up as a new genre of pain relief therapy for future with much broader efficacy range and less adverse effects.

Insight by :
Anurag Mathur
Associate Analyst
DelveInsight Business Research

 

Anticoagulants (VTE & AF) Therapeutics Market is estimated to reach $17.2 billion by 2020

Posted on

The Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020.

DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Anticoagulants andAtrial Fibrillation and Venous Thromboembolism. The Report majorlyemphasizes on the global Anticoagulants market size and market size of theAnticoagulants by 7 Major Markets (United States, EU5 (France, Germany,Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial

Fibrillation and Venous thromboembolism along with the market sales of the Key drugs by VTE and AF indications. It provides comprehensive review of Market Drivers, Market Barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.

Global AF market was $7.2 billion in 2015 and is expected to grow to $12.5 billion by 2020 with an compound annual growth rate (CAGR) of 11.62% where as Global VTE market was $4.2 billion in 2015 and is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%

With the recommendation of usage of novel oral anticoagulants (NOAC) by International guidelines in line with their established safety, efficacy and compliance, we expect decrease of warfarin use at a CAGR of negative 3.20% from 2015-2020 due to patient preferences in switching from warfarin to NOAC at a significant rate.  Novel Oral Anticoagulants (NOAC) will continue to be first-line oral agents, accounting for 70% of major-market sales in 2015.

Insights from recent studies clearly indicates that Physicians are relatively satisfied with the NOACs due to its efficacy and positive safety profiles without the need for anticoagulation monitoring and
dose frequencies. Conventional therapies (i.e., Warfarin) will remain entrenched as first-line therapies for most of the AF and VTE patients, followed by novel oral anticoagulants (NOAC) in the developing and underdeveloped countries due to the high cost of NOAC medications.

For more information on this report email us at info@delveInsight.com.

DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

Global atrial fibrillation market is expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%

Posted on

Global AF market was $7.2 billion in 2015 and expected to grow to $12.5 billion by 2020 with and compound annual growth rate (CAGR) of 11.62%. There are four NOACs which are indicated for the treatment of AF such as Xarelto, Eliquis, Pradaxa and Savaysa.

DelveInsight Atrial Fibrillation-Market Insights & Drugs Sales Forecast (AF) -2020 provides an overview of Atrial Fibrillation indication. The Report majorly emphasize on the global Anticoagulants market size and market size of the Anticoagulants by 7Major Markets (United States, EU5 (France, Germany, Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial Fibrillation along with the market sales of the Key drugs by AF.  The Report provides comprehensive review of Market Drivers, Market barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

With the new guideline by regulatory agencies has promoted the use of NOACs over warfarin. Atrial Fibrillation guidelines has also encouraged to use CHA2DS2-VASc score instead of the CHADS2 score for assessing stroke risk, which will cause a larger proportion of lower risk patients to receive anticoagulant treatment.

For more information email us @ info@delveinsight.com.

Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF)-2020- A DelveInsight Report

Posted on

According to DelveInsight researchers, the Anticoagulants (VTE & AF) Therapeutics Market was around $11.4 billion in 2015 and is estimated to reach $17.2 billion by 2020 growing at a CAGR of 8.59% from 2015 to 2020.

DelveInsight Report “Anticoagulants-Market Insights & Drugs Sales Forecast (VTE & AF) -2020” provides an overview of the Anticoagulants andAtrial Fibrillation and Venous Thromboembolism. The Report majorlyemphasizes on the global Anticoagulants market size and market size of theAnticoagulants by 7 Major Markets (United States, EU5 (France, Germany,Italy, Spain, UK) and Japan). The Report also covers the market size of Atrial

Fibrillation and Venous thromboembolism along with the market sales of the Key drugs by VTE and AF indications. It provides comprehensive review of Market Drivers, Market Barriers, Anticoagulants with coverage of detailed profile, Cost of therapy, Safety and Efficacy profiles and SWOT analysis.

The global anticoagulants market is categorized based on different classes like vitamin K reductase Inhibitor, heparin, low molecular weight heparin, Factor Xa Inhibitor and thrombin inhibitors.

Global AF market was $7.2 billion in 2015 and is expected to grow to $12.5 billion by 2020 with an compound annual growth rate (CAGR) of 11.62% where as Global VTE market was $4.2 billion in 2015 and is expected to grow to $4.75 billion by 2020 with a compound annual growth rate (CAGR) of 2.44%

With the recommendation of usage of novel oral anticoagulants (NOAC) by International guidelines in line with their established safety, efficacy and compliance, we expect decrease of warfarin use at a CAGR of negative 3.20% from 2015-2020 due to patient preferences in switching from warfarin to NOAC at a significant rate.  Novel Oral Anticoagulants (NOAC) will continue to be first-line oral agents, accounting for 70% of major-market sales in 2015.

Insights from recent studies clearly indicates that Physicians are relatively satisfied with the NOACs due to its efficacy and positive safety profiles without the need for anticoagulation monitoring and

dose frequencies. Conventional therapies (i.e., Warfarin) will remain entrenched as first-line therapies for most of the AF and VTE patients, followed by novel oral anticoagulants (NOAC) in the developing and underdeveloped countries due to the high cost of NOAC medications.

For more information on this report email us at info@delveInsight.com.

DelveInsight is a leading Business Consulting and Market Research Firm. DelveInsight helps the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.

DelveInsight Business Research

+91-11-4568 9769

info@delveinsight.com

Pancreatic Cancer – Market Insights, Epidemiology and Market Forecast-2020

Posted on

DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products.

DelveInsight expertise has expanded from an initial focus on Pipeline & Marketed Reports to Market Forecasting and Epidemiology Reports.

Pancreatic Cancer -Market Insights, Epidemiology and Market Forecast-2020, report provides an insight on the forecast of a indication over a period of time which helps an organization to better understand the business development strategies from present and futuristic point of view.

Pancreatic Cancer-Market Insights, Epidemiology and Market Forecast-2020, provides clients with the detailed insights into epidemiology and market forecast of the indication in these countries. This report majorly includes:

  • Report covers the disease overview including etiology, path physiology, symptoms, diagnosis, disease management and current treatment options.
  • Marketed information including available prescription drugs, its patent and exclusivity details followed by drug sales till 2018.
  • The Report also covers the detailed global historical and forecasted epidemiological data covering United States, EU5 and Japan from 2010-2020.
  • It also provides Market size of Pancreatic Cancer for United States, EU5 and Japan from 2010 and forecasted Market size to 2020. This epidemiological analysis report will aid in the development of business strategies by providing a deep understanding of the trend shaping and driving the global insight market. Along with that, it quantifies the patient populations in the global indication market to improve product design, pricing, and launch plans.

DelveInsight is offering the Report at a price of USD 4,950 as a single user license, USD 9,900 as a site license and USD 14,850 as a Global/Enterprise License.

For more information on Indication – Market insights, Epidemiology and Market Forecast 2010-2020, email at info@delveInsight.com

Note: These types of reports require 7-10 working days.

About Us:

DelveInsight is a leading Business Consulting and Market Research Firm.  DelveInsight helps the clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.